Revolution Medicines, Inc. (RVMD) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $140.52 (-2.50%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 14, 2026 | Robert Burns | H.C. Wainwright | $169.00 | +20.3% |
| Feb 26, 2026 | Eva Fortea Verdejo | Wells Fargo | $144.00 | +2.5% |
| Jan 27, 2026 | Jay Olson | Oppenheimer | $150.00 | +6.7% |
| Jan 21, 2026 | Leonid Timashev | RBC Capital | $140.00 | -0.4% |
| Jan 13, 2026 | Andrea Newkirk | Goldman Sachs | $73.00 | -48.1% |
| Nov 3, 2025 | Leonid Timashev | RBC Capital | $77.00 | -45.2% |
| Oct 17, 2025 | Alex Stranahan | National Bank | $80.00 | -43.1% |
| Aug 19, 2025 | Kelsey Goodwin | Piper Sandler | $75.00 | -46.6% |
| May 14, 2025 | Robert Burns | H.C. Wainwright | $72.00 | -48.8% |
| Apr 1, 2025 | Benjamin Burnett | Stifel Nicolaus | $64.00 | -54.5% |
| Jan 8, 2025 | Eliana Merle | UBS | $71.00 | -49.5% |
| Nov 7, 2024 | Joseph Catanzaro | Piper Sandler | $70.00 | -50.2% |
| Nov 4, 2024 | Raghuram Selvaraju | H.C. Wainwright | $62.00 | -55.9% |
| Oct 28, 2024 | Michael Schmidt | Guggenheim | $82.00 | -41.6% |
| Oct 28, 2024 | Jay Olson | Oppenheimer | $60.00 | -57.3% |
| Oct 15, 2024 | Jay Olson | Oppenheimer | $55.00 | -60.9% |
| Sep 17, 2024 | Joseph Catanzaro | Piper Sandler | $57.00 | -59.4% |
| Aug 8, 2024 | Ami Fadia | Needham | $61.00 | -56.6% |
| Jul 15, 2024 | Robert Driscoll | Wedbush | $59.00 | -58.0% |
| Apr 19, 2024 | Ben Burnett | Stifel Nicolaus | $43.00 | -69.4% |
Top Analysts Covering RVMD
RVMD vs Sector & Market
| Metric | RVMD | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 26 | 8 | 18 |
| Target Upside | +10.2% | +1150.3% | +14.9% |
| P/E Ratio | -24.34 | 6.89 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $7M | $68M | $149M | 14 |
| 2027-03-31 | $32M | $129M | $226M | 4 |
| 2027-06-30 | $38M | $152M | $265M | 4 |
| 2027-09-30 | $51M | $203M | $356M | 5 |
| 2027-12-31 | $97M | $391M | $684M | 4 |
| 2028-03-31 | $37M | $150M | $263M | 3 |
| 2028-06-30 | $44M | $175M | $306M | 3 |
| 2028-09-30 | $45M | $180M | $315M | 5 |
| 2028-12-31 | $45M | $180M | $315M | 3 |
| 2029-12-31 | $635M | $2.97B | $9.89B | 12 |
| 2030-12-31 | $993M | $4.65B | $15.47B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-8.32 | $-7.62 | $-6.23 | 17 |
| 2027-03-31 | $-3.11 | $-1.57 | $-0.04 | 5 |
| 2027-06-30 | $-2.85 | $-1.44 | $-0.03 | 5 |
| 2027-09-30 | $-2.49 | $-1.26 | $-0.03 | 5 |
| 2027-12-31 | $-1.71 | $-0.86 | $-0.02 | 5 |
| 2028-03-31 | $-2.92 | $-1.48 | $-0.04 | 7 |
| 2028-06-30 | $-2.77 | $-1.40 | $-0.03 | 6 |
| 2028-09-30 | $-2.75 | $-1.39 | $-0.03 | 6 |
| 2028-12-31 | $-2.79 | $-1.41 | $-0.03 | 7 |
| 2029-12-31 | $-0.04 | $1.80 | $7.25 | 10 |
| 2030-12-31 | $-0.17 | $7.76 | $31.25 | 5 |
Frequently Asked Questions
What is the analyst consensus for RVMD?
The consensus among 26 analysts covering Revolution Medicines, Inc. (RVMD) is Buy with an average price target of $124.36.
What is the highest price target for RVMD?
The highest price target for RVMD is $169.00, set by Robert Burns at H.C. Wainwright on 2026-04-14.
What is the lowest price target for RVMD?
The lowest price target for RVMD is $30.00, set by Dane Leone at Raymond James on 2023-11-16.
How many analysts cover RVMD?
26 analysts have issued ratings for Revolution Medicines, Inc. in the past 12 months.
Is RVMD a buy or sell right now?
Based on 26 analyst ratings, RVMD has a consensus rating of Buy (2.00/5) with a +10.2% upside to the consensus target of $124.36.
What are the earnings estimates for RVMD?
Analysts estimate RVMD will report EPS of $-7.62 for the period ending 2026-12-31, with revenue estimated at $68M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.